Close Menu

NEW YORK (GenomeWeb) – Several equity research today initiated coverage of Guardant Health with favorable ratings, citing the firm's strong liquid biopsy testing portfolio — and especially its Guardant360 assay — as reasons for their optimism.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.